Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsbreastpatienteligiblestandard
  Phrases that lowered it: kneeefficacyclinicallysafetybleeding
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 6.1% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 98.8% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 14 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty NCT01720108 · started 2013 · scored riskier than 48% of active trials completed
• A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants NCT06454630 · started 2024 · scored riskier than 48% of active trials completed
• Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery NCT01431456 · started 2013 · scored riskier than 25% of active trials completed
• Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty NCT02271399 · started 2014 · scored riskier than 10% of active trials completed
• A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants NCT05618808 · started 2023 · scored riskier than 31% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.